

1/5/1 (Item 1 from file: 351)  
DIALOG(R) File 351:Derwent WPI  
(c) 2001 Derwent Info Ltd. All rts. reserv.

010265930 \*\*Image available\*\*  
WPI Acc No: 1995-167185/199522  
XRAM Acc No: C95-077405

**Aq. suspension liq. for treating cataract and corneal disorders -  
comprises 5-(3-ethoxy-4-N-pentyl-oxyphenyl)-thiazolidine-2,4- dione fine  
crystals, aq. macromolecular cpd.,, chloro-butanol and benzalkonium  
chloride**

Patent Assignee: SENJU SEIYAKU KK (SENP ); TAKEDA CHEM IND LTD (TAKE )  
Number of Countries: 001 Number of Patents: 002  
Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
JP 7089857	A	19950404	JP 94176420	A	19940728	199522 B
JP 2787131	B2	19980813	JP 94176420	A	19940728	199837

Priority Applications (No Type Date): JP 93189629 A 19930730

Patent Details:

Patent No	Kind	Lan	Pg	Main IPC	Filing Notes
JP 7089857	A		5	A61K-031/425	
JP 2787131	B2		4	A61K-031/425	Previous Publ. patent JP 7089857

Abstract (Basic): JP 7089857 A

Aq. suspension liq. of fine crystal of  
5-(3-ethoxy-4-n-pentyl-oxyphenyl)thiazolidine-2,4-dione (CGT-112)  
comprises (1) aq. macromolecular cpd. (2) chlorobutanol and (3)  
benzalkonium chloride and/or paraoxybenzoic acid ester.

The dia. of the fine crystals of CT-112 is pref. less than 10  
mcirons. Aq. macromolecular cpd. is pref. hydroxypropyl methyl  
cellulose. Ester of bennzalkonium chloride and/or paraoxy benzoate is  
pref. paraoxybenzoate ester. The amt. of aq. macromolecular cpd. and  
CT-112 is pref. 0.001-5.0 w/v% and 0.01-5.0 w/v%, respectively. The amt.  
of benzalkonium chloride and/or paraoxybenzoate ester is 0.0005-0.1  
w/v%.

USE/ADVANTAGE - CT-112 is used for the prevention and treatment of  
cataract, corneal disorder and iridocyclitis caused by diabetes. CT-112  
is homogeneously dispersed in the aq. suspension as the size of the  
particles is less than 10 microns. The liq. is stable over a long  
period and prevents pain when administered as eye drops.

In an example, NaOH (1.4g), AcONa (2g) were dissolved in purified  
water (200ml), and CT-112 (10g) was added to the soln., 200 ml soln.  
contg. HPMC (2g) was added to the soln.. The soln. was sterilised by  
filtration (pH: 11.7) 0.5 N HCl was added dropwise to the soln. with  
stirring to adjust the pH at 5.5. Sterilised soln. (2500ml) contg.  
concn. glycerol (88g), paraoxy methyl benzoate (1g), HPMC (2g),  
chlorobutanol (12g), sodium edetate (0.8g) and sodium acetate (2g) was  
added. Then purified water was added to make up 4000 ml soln.

Dwg.0/0

Title Terms: AQUEOUS; SUSPENSION; LIQUID; TREAT; CATARACT; CORNEA; DISORDER  
; COMPRISE; ETHOXY; N; PENTYL; THIAZOLIDINE; DI; ONE; FINE; CRYSTAL;  
AQUEOUS; MACROMOLECULAR; COMPOUND; CHLORO; BUTANOL; BENZALKONIUM;  
CHLORIDE

Derwent Class: B03; B07

International Patent Class (Main): A61K-031/425

International Patent Class (Additional): A61K-009/107; A61K-047/10;

A61K-047/14; C07D-277/34

File Segment: CPI

1/5/2 (Item 1 from file: 347)  
DIALOG(R) File 347:JAPIO  
(c) 2001 JPO & JAPIO. All rts. reserv.

04797257

AQUEOUS SUSPENSION SOLUTION

PUB. NO.: 07-089857 JP 7089857 A]  
PUBLISHED: April 04, 1995 (19950404)  
INVENTOR(s): NAKAYAMA HISAYUKI  
USHIO KAZUMICHI  
INADA KATSUHIRO  
APPLICANT(s): SENJU PHARMACEUT CO LTD [402938] (A Japanese Company or  
Corporation), JP (Japan)  
TAKEDA CHEM IND LTD [000293] (A Japanese Company or  
Corporation), JP (Japan)  
APPL. NO.: 06-176420 [JP 94176420]  
FILED: July 28, 1994 (19940728)  
INTL CLASS: [6] A61K-031/425; A61K-009/107; C07D-277/34  
JAPIO CLASS: 14.4 (ORGANIC CHEMISTRY -- Medicine); 14.1 (ORGANIC CHEMISTRY  
-- Organic Compounds); 14.2 (ORGANIC CHEMISTRY -- High  
Polymer Molecular Compounds)  
JAPIO KEYWORD: R042 (CHEMISTRY -- Hydrophilic Plastics)

ABSTRACT

PURPOSE: To obtain a stable aqueous suspension solution containing  
5-(3-ethoxy-4-n-pentyloxyphenyl) thiazolidine-2,4-dione useful as a  
therapeutic agent for corneal disorder as an active ingredient.

CONSTITUTION: This aqueous suspension solution of fine crystal of  
5-(3-ethoxy-4-n-pentyloxyphenyl)thiazolidine-2,4-dione contains a  
water-soluble polymer, chlorobutanol and benzalkonium chloride and/or  
p-oxybenzoic ester.

2/5/1 (Item 1 from file: 351)  
DIALOG(R) File 351:Derwent WPI  
(c) 2001 Derwent Info Ltd. All rts. reserv.

012380094 \*\*Image available\*\*

WPI Acc No: 1999-186201/199916

XRAM Acc No: C99-054724

Use of 3-alkoxy-pyridine derivative with non-peptide angiotensin II  
acceptor antagonism activity - to prevent or treat intravascular membrane  
hypertrophy due to e.g. reconstruction after PTCA and arteriosclerosis

Patent Assignee: MEIJI SEIKA KAISHA LTD (MEIJ )

Number of Countries: 001 Number of Patents: 001

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
JP 11035464	A	19990209	JP 97197630	A	19970723	199916 B

Priority Applications (No Type Date): JP 97197630 A 19970723

Patent Details:

Patent No	Kind	Lan Pg	Main IPC	Filing Notes
JP 11035464	A	4	A61K-031/44	

Abstract (Basic): JP 11035464 A

Use of a 3-alkoxypyridine derivative of formula (I) or a salt with  
non-peptide angiotensin II acceptor antagonism activity for preventing  
or treating intravascular membrane hypertrophy, is new. A = COOH or  
tetrazol-5-yl; R1, R2 = H or lower alkyl; R3 = H, lower alkyl  
(optionally substituted by halo, 3-7C cycloalkyl, 5-6-membered  
saturated heterocyclic group containing 1 N and optionally substituted  
by lower alkyl, or H2NCO optionally substituted by lower alkyl), lower  
alkenyl, 3-7C cycloalkyl or benzyl (optionally ring-substituted by  
halo, lower alkyl, halo(lower alkyl) or lower alkoxy).

ADVANTAGE - (I) are useful for preventing and treating diseases due  
to reconstruction after PTCA and arteriosclerosis.

Dwg.0/0

Title Terms: ALKOXY; PYRIDINE; DERIVATIVE; NON; PEPTIDE; ANGIOTENSIN;  
ACCEPT; ANTAGONIST; ACTIVE; PREVENT; TREAT; INTRAVASCULAR; MEMBRANE;  
HYPERTROPHY; AFTER; ARTERIOSCLEROSIS

Derwent Class: B03

International Patent Class (Main): A61K-031/44

International Patent Class (Additional): C07D-213/69; C07D-401/12

File Segment: CPI

2/5/2 (Item 1 from file: 347)  
DIALOG(R) File 347:JAPIO  
(c) 2001 JPO & JAPIO. All rts. reserv.

06093948 \*\*Image available\*\*

MEDICINE CONTAINING 3-ALKOXYPYRIDINE DERIVATIVE AND USED FOR PREVENTING OR  
TREATING VASCULAR INTIMAL HYPERPLASIA

PUB. NO.: 11-035464 A]  
PUBLISHED: February 09, 1999 (19990209)  
INVENTOR(s): HACHISU MITSUGI  
YASUDA HISAE  
IIDA HIROYUKI  
FUJISHIMA KAZUYUKI  
KATANO KIYOAKI  
APPLICANT(s): MEIJI SEIKA KAISHA LTD  
APPL. NO.: 09-197630 [JP 97197630]  
FILED: July 23, 1997 (19970723)  
INTL CLASS: A61K-031/44; A61K-031/44

#### ABSTRACT

PROBLEM TO BE SOLVED: To obtain a medicine for preventing or treating

Vascular intimal hyperplasia by using a specific 3-alkoxypyridine derivative having a non-peptide angiotensin II receptor-antagonizing action as an active ingredient.

SOLUTION: This medicine contains a 3-alkoxypyridine derivative of the formula (A is carboxyl or tetrazol-5-yl; R1 and R2 are each H or an alkyl; R3 is H, an alkyl, an alkenyl, a cycloalkyl or benzyl) having a non-peptide angiotensin II receptor-antagonizing action or its pharmacologically acceptable non-toxic salt as an active ingredient. The compound of the formula is preferably especially 2,6-dimethyl-3-methoxy-4-[2'-(tetrazol-5-yl)biphenyl-4-yl]methoxypyridine. The compound is preferably added in an amount of 1-70 wt.% to a pharmaceutical composition, and preferably administered at a daily dose of about 0.1-300 mg for an adult.

COPYRIGHT: (C)1999,JPO